Frontiers in Virology | Antivirals and Vaccines

Original Research

Published on 24 May 2022

Immune Responses of a Novel Bi-Cistronic SARS-CoV-2 DNA Vaccine Following Intradermal Immunization With Suction Delivery

in Antivirals and Vaccines

Moonsup Jeong
Sagar B. Kudchodkar
Areum Gil
Bohyun Jeon
Gee Ho Park
Youngran Cho
Hyojin Lee
Mi Sun Cheong
Wonil Kim
Yun-Ho Hwang

Frontiers in Virology

doi 10.3389/fviro.2022.891540

5,016 views
12 citations

Review

Published on 29 Apr 2022

Therapeutic Potential of Long Non-Coding RNAs of HIV-1, SARS-CoV-2, and Endogenous Retroviruses

in Antivirals and Vaccines

Andrea Virginia Ruiz Ramírez
Ernesto Prado Montes de Oca

Frontiers in Virology

doi 10.3389/fviro.2022.849349

3,426 views
4 citations

Original Research

Published on 14 Apr 2022

Identification of Compounds With Antiviral Activity Against SARS-CoV-2 in the MMV Pathogen Box Using a Phenotypic High-Throughput Screening Assay

in Antivirals and Vaccines

Laís D. Coimbra
Alexandre Borin
Marina Fontoura
Humberto D. Gravina
Alice Nagai
Jacqueline Farinha Shimizu
Karina Bispo-dos-Santos
Fabiana Granja
Paulo S. L. Oliveira
Kleber G. Franchini

Frontiers in Virology

doi 10.3389/fviro.2022.854363

5,478 views
8 citations

Original Research

Published on 07 Apr 2022

Highly Efficient Autologous HIV-1 Isolation by Coculturing Macrophage With Enriched CD4+ T Cells From HIV-1 Patients

in Antivirals and Vaccines

Cristina Xufré
Tanía González
Lorna Leal
Charles M. Trubey
Jeffrey D. Lifson
José María Gatell
José Alcamí
Núria Climent
Felipe García
Sonsoles Sánchez-Palomino

Frontiers in Virology

doi 10.3389/fviro.2022.869431

2,555 views

Brief Research Report

Published on 15 Dec 2021

Iota-Carrageenan Prevents the Replication of SARS-CoV-2 in a Human Respiratory Epithelium Cell Line in vitro

in Antivirals and Vaccines

Augusto Varese
Ana Paletta
Ana Ceballos
Carlos Adolfo Palacios
Juan Manuel Figueroa
Andrea Vanesa Dugour

Frontiers in Virology

doi 10.3389/fviro.2021.746824

24,135 views
13 citations

Review

Published on 23 Aug 2021

Defining Efficacy of Chikungunya Virus Candidate Vaccines: Different Endpoints Derived From the Virus—Cytokine—Ferritin (VCF) Model

in Antivirals and Vaccines

Stephanie M. Lim
Sudip K. Dutta
Byron E. E. Martina

Frontiers in Virology

doi 10.3389/fviro.2021.693439

4,397 views
1 citation

Specialty Grand Challenge

Published on 24 May 2021

Vaccines and Antivirals: Grand Challenges and Great Opportunities

in Antivirals and Vaccines

Graciela Andrei

Frontiers in Virology

doi 10.3389/fviro.2021.666548

12,123 views
25 citations

Navigation group

Articles

Immune Responses of a Novel Bi-Cistronic SARS-CoV-2 DNA Vaccine Following Intradermal Immunization With Suction Delivery

Therapeutic Potential of Long Non-Coding RNAs of HIV-1, SARS-CoV-2, and Endogenous Retroviruses

Identification of Compounds With Antiviral Activity Against SARS-CoV-2 in the MMV Pathogen Box Using a Phenotypic High-Throughput Screening Assay

Highly Efficient Autologous HIV-1 Isolation by Coculturing Macrophage With Enriched CD4+ T Cells From HIV-1 Patients

Iota-Carrageenan Prevents the Replication of SARS-CoV-2 in a Human Respiratory Epithelium Cell Line in vitro

Defining Efficacy of Chikungunya Virus Candidate Vaccines: Different Endpoints Derived From the Virus—Cytokine—Ferritin (VCF) Model

Vaccines and Antivirals: Grand Challenges and Great Opportunities